NICE backs Yervoy for first-line melanoma

The U.K.'s NICE issued final draft guidance recommending Yervoy ipilimumab from Bristol-Myers Squibb Co. (NYSE:BMY) as first-line treatment of unresectable or metastatic advanced malignant melanoma. T...